rondecabtagene autoleucel
Generic: ronde-cel·Code: LYL314
rondecabtagene autoleucel: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Lyell Immunopharma, Inc. (LYEL) | Phase 3 |
Clinical Trials (1)
A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting
Frequently asked questions
Who is developing rondecabtagene autoleucel?
rondecabtagene autoleucel is being developed by Lyell Immunopharma, Inc..
How many clinical trials involve rondecabtagene autoleucel?
BioSniper tracks 1 clinical trial involving rondecabtagene autoleucel.
Get deeper analysis on rondecabtagene autoleucel
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis